Racial Heterogeneity Unlikely to Affect RAS Blocker Benefits, Re-Analysis Suggests
Key Insights
A re-analysis of clinical trial data suggests that the heterogeneity between Black and White patients does not substantially impact the clinical benefit of RAS blockers (search).
The findings address concerns raised about potential biases in a meta-analysis of clinical trials on race and renin-angiotensin system (RAS) blockers.
Results from the re-analysis, comparing Black and White patients, were nearly identical to the original analysis comparing Black and non-Black patients.
A re-analysis of clinical trial data indicates that racial heterogeneity is unlikely to significantly affect the clinical benefits derived from renin-angiotensin system (RAS) blockers. This conclusion addresses concerns raised regarding potential biases in a meta-analysis that examined the impact of race on the effectiveness of RAS blockers (search).
In response to concerns about heterogeneity between Black and White patients, researchers conducted additional analyses to specifically compare the clinical benefits of RAS blockers (search) in these two groups. The results of this re-analysis closely mirrored the findings of the original study, which compared Black and non-Black patients. According to the authors, the similarity in outcomes suggests that the heterogeneity across these patient groups was not substantial, as some had anticipated.
The initial meta-analysis and subsequent re-analysis contribute to the understanding of how RAS blockers (search) perform across different racial groups, providing valuable insights for clinicians and researchers in the field.